Lund-based biotech company SenzaGen has developed animal-free test methods to assess allergenicity of substances, directed towards four industry segments: pharmaceuticals, medical devices, cosmetics, and the chemicals industry. Recently, the company published its year-end report for 2020, which was a period of transition with focus on the market, sales and regulatory processes. SenzaGen’s CEO Axel Sjöblad visited BioStock’s studio and talked about the report, ongoing projects and what we can expect from the company in 2021.
Watch the interview with SenzaGen’s CEO Axel Sjöblad below.
The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.